Covidien Releases Clinical Trial Results Supporting the Use of Endoscopic Ablation Therapy as Barrett’s Esophagus Treatment

Covidien, Mansfield, Mass.-based healthcare products company, has announced the results of a clinical trial designed to test the efficacy of its Barrx RF Ablation System as a Barrett’s esophagus treatment.

Advertisement

The randomized, prospective, multicenter, controlled trial involved 136 Barrett’s esophagus patients with low-grade dysplasia. After the last endoscopy visit, 90 percent of the patients treated with ablation demonstrated no signs of Barrett’s esophagus tissue.

More Articles on Gastroenterology:
8 Trends Shaping the Present & Future of Gastroenterology
PENTAX Launches Video Processor With PENTAX i-SCAN
Vision-Sciences Names Howard Zauberman Interim CEO

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.